Generali Investments CEE investicni spolecnost a.s. Takes Position in Solventum Co. (NYSE:SOLV)

Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 5,108 shares of the company’s stock, valued at approximately $337,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum in the 3rd quarter worth $125,488,000. Trian Fund Management L.P. raised its position in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares during the period. Point72 Asset Management L.P. purchased a new position in Solventum in the 3rd quarter worth $50,948,000. Nordea Investment Management AB raised its position in Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after purchasing an additional 431,986 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Solventum in the 4th quarter worth $18,583,000.

Analyst Ratings Changes

A number of equities analysts recently commented on SOLV shares. Wells Fargo & Company lifted their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler lifted their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Bank of America lifted their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. Finally, Mizuho boosted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Solventum currently has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Price Performance

SOLV stock opened at $77.96 on Monday. The firm’s 50-day moving average price is $73.65 and its two-hundred day moving average price is $70.71. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The stock has a market capitalization of $13.49 billion and a price-to-earnings ratio of 28.35. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.